

1 QUINN EMANUEL URQUHART &
 2 SULLIVAN, LLP
 3 Kevin P.B. Johnson (Bar No. 177129)
 kevinjohnson@quinnemanuel.com
 4 Victoria F. Maroulis (Bar No. 202603)
 victoriamaroulis@quinnemanuel.com
 Andrew J. Bramhall (Bar No. 253115)
 andrewbramhall@quinnemanuel.com
 5 555 Twin Dolphin Drive, 5th Floor
 Redwood Shores, California 94065-2139
 Telephone: (650) 801-5000
 Facsimile: (650) 801-5100

7 QUINN EMANUEL URQUHART &
 8 SULLIVAN, LLP
 Valerie Lozano (Bar No. 260020)
 valerielozano@quinnemanuel.com
 9 865 Figueroa Street, 10th Floor
 Los Angeles, California 90017
 Telephone: (213) 443-3000
 Facsimile: (213) 443-3100

12 Attorneys for Defendant and Counterclaim-
 Plaintiff NATERA, INC.

1 QUINN EMANUEL URQUHART &
 SULLIVAN, LLP
 Anne S. Toker (*pro hac vice*)
 annetoker@quinnemanuel.com
 51 Madison Avenue, 22nd Floor
 New York, New York 10010-1601
 Telephone: (650) 801-5000
 Facsimile: (650) 801-5100

QUINN EMANUEL URQUHART &
 SULLIVAN, LLP
 Derek L. Shaffer (Bar No. 212746)
 1300 I Street, Suite 900
 Washington, DC 20005
 derekshaffer@quinnemanuel.com
 Telephone: (202) 538-8000
 Facsimile: (202) 538-8100

12 UNITED STATES DISTRICT COURT
 13 NORTHERN DISTRICT OF CALIFORNIA,
 14 SAN FRANCISCO DIVISION

17 GUARDANT HEALTH, INC.

18 Plaintiff and
 19 Counterclaim-Defendant,
 20 vs.

21 NATERA, INC.

22 Defendant and
 23 Counterclaim-Plaintiff.

CASE NO. 3:21-CV-04062-EMC

**NATERA, INC.'S OBJECTION TO
 GUARDANT'S COUNSEL IMPROPERLY
 TESTIFYING TO THE JURY**

Hearing: November 12, 2024
 Time: 8:00 a.m.
 Place: Courtroom 5, 17th Floor
 Judge: Hon. Edward M. Chen

24

25

26

27

28

1 Natera Inc. (“Natera”) objects to counsel for Guardant Health, Inc. (“Guardant”) improperly
 2 arguing and mischaracterizing evidence to the jury during witness exams. Attorney argument is not
 3 evidence, and it is impermissible for Guardant’s counsel to continually mischaracterize evidence to
 4 the jury. Despite this, Guardant’s counsel continues to make objectionable preambles before or
 5 while questioning witnesses, which include misstating evidence, falsely suggesting witnesses are
 6 lying, and belittling witnesses. We are still at the outset of the trial, and witness examinations are
 7 not the appropriate time or forum for attorneys to argue the evidence or to testify. Guardant’s
 8 counsel can save their soliloquies and one-liners for closing. Natera is raising this issue with the
 9 Court and outside of the purview of the jury because it has been and will continue to be prejudiced
 10 if it has to either continuously object to Guardant’s counsel’s improper and misleading tactics,
 11 suggesting to the jury it is attempting to prevent evidence from being heard, or allow the
 12 improprieties to continue. Natera requests that the Court preclude Guardant’s counsel from offering
 13 improper attorney argument and mischaracterizations of the evidence.

14 There are many examples where Guardant’s counsel has repeatedly testified and
 15 mischaracterized the evidence, a few of which are included below:

16 • Ex. A (2024/11/07 Trial Tr.) at 578:6-13.

17 Q. And you didn’t tell the sales force that the Reinert study, the Danish
 18 study, excluded 150 samples because they were 4 milliliters or less, the
 19 amount that was used in all the Reveal samples? You didn’t tell them
 20 that, did you?

21 A. *I didn’t even know that. If that is true or not, I don’t know.*

22 Q. *It’s true.*

23 • Ex. A (2024/11/07 Trial Tr.) at 567:8-13.

24 Q. Okay. I want to shift gears and *discuss with you Signatera’s apples-*
to-oranges comparison chart, and that would be Exhibit 126, which is
already in evidence. You helped prepare this, didn’t you?

25 A. I’m not -- if it’s the grid, then, yes. I’m not seeing anything on my
 26 screen, though.

27 • Ex. A (2024/11/07 Trial Tr.) at 585:17-24.

28 Q. Let’s show you Slide 3 of that exhibit. That’s Page 3. And this slide
 29 -- if you look up here at this box at the top right, it says [as read]: “No
 changes to this grid. All points remain valid.”

A. That is true.

Q. *But they weren’t, were they? They weren’t still valid. You knew*
better, didn’t you?

1 A. I did not.

2 • Ex. A (2024/11/07 Trial Tr.) at 520:13-521:8.

3 [after listing the members of Project Solar at Natera]
 4 **Q. It sounds like this was a pretty big threat.** And that
 5 SOLAR squad met every week; right?

6 A. We met every week, yes.

7 Guardant's counsel has also improperly suggested that witnesses who are on the stand under
 8 oath are lying by mischaracterizing documents or deposition testimony without actually showing
 9 them the documents, for example:

10 • Compare Ex. A (2024/11/07 Trial Tr.) at 532:18-533:10 with Ex. B (Masukawa Dep. Tr.) at
 11 86:9-12 ("Q. But I'm right that you wanted MolDX not to approve Guardant for
 12 reimbursement? A. *Incorrect. We wanted MolDX to look at the evidence in the right way.*").

13 Q. So even before the commercial launch of Reveal, you and Dr.
 14 Aleshin were already thinking of how you could interfere with Guardant
 15 Health's ability to get coverage from Medicare; right?

16 A. We wanted to make sure Medicare was evaluating the evidence
 17 appropriately.

18 **Q. Yeah, so they wouldn't cover it, as you said in your deposition
 19 elsewhere; right?**

20 A. If it didn't meet the standard that we set, then --

21 Q. Not my question. Let me ask it again. Your goal here was to keep
 22 Guardant Health from getting coverage by Medicare for its Reveal test?

23 A. My goal was to have MolDX educated and evaluate the evidence in
 24 the right way.

25 **Q. So it would turn it down for Medicare, as you said in your
 26 deposition?**

27 A. If MolDX had approved Guardant with the evidence they had, that
 28 would have been MolDX's decision.

19 • Compare Ex. A (2024/11/07 Trial Tr.) at 496:14-496:20, with Ex. C (Masukawa LinkedIn)
 20 (correctly reflecting that Kevin Masukawa worked for Natera from 2019 through 2023).

21 Q. Okay. Now that we've gotten that out of the way, ***you worked for
 22 Natera from November 2015 to October of 2023; is that right?***

23 A. **No.**

24 Q. Oh, I'm sorry. ***I'm just going from your LinkedIn.*** What were --
 25 what were the dates?

26 A. October 2019 until October-November 2023, four years.

27 Guardant's counsel also regularly cuts witnesses off, and belittles them in front of the jury,
 28 for example:

29 • Ex. A (2024/11/07 Trial Tr.) at 589:1-22.

30 **Q. That doesn't sound very consistent with your scientific training,
 31 Doctor. It's not, is it?**

32 A. What doesn't?

1 Q. You've got a PhD in chemistry; right?

2 A. Yes.

3 Q. If you were running a chemistry experiment and somebody came
4 long and said, "Hey, somebody's complaining that your analysis is
5 wrong and it's false and you're putting stuff out there that's false," the
6 scientific method would require you to say, "Let me see that and
7 examine it"; right?

8 A. Well, it would require me to let me see the data that was in there. I
9 don't care what's in the letter, actually.

10 Q. How about, "Let me see the letter so I can see what data they cite in
11 the letter"? *I mean, this is all -- this is all pretty basic stuff, Doctor. If*
12 *you were a scientist, you'd want to see it, Wouldn't you?* If somebody
13 says "Your whole experiment is based on false data, false advertising,
14 you're wrong," you'd say, "Let me see that. I want to look at it, see if I
15 can falsify my experiment"; right? A. I trust our Legal Department.

- 9 • Ex. A (2024/11/07 Trial Tr.) at 513:21-514:15

10 Q. That was something you reviewed in preparing to testify; right?

11 A. Yes.

12 Q. You reviewed documents. You reviewed slides. And you know that
13 was directed specifically at Reveal; right?

14 A. Yes. It was to address the misleading claims that we saw.

15 Q. That's not what I asked you. I understand that's what you want to
16 say. That's not what I asked you. What I asked you was: Project
17 SOLAR was directed at Reveal; right?

18 A. I think it was directed at the claims that Reveal was making, correct.

19 Q. *Is that something you've been preparing to say in regard to any*
20 *question that I ask you about SOLAR?*

21 A. No.

22 Q. *Is that a canned answer that you have in case I ask you anything*
23 *about SOLAR?*

24 A. No.

25 Q. *Because it sure sounds like it, Doctor.*

26 A. It is the truth.

- 19 • Ex. A (2024/11/07 Trial Tr.) at 521:24-522:2.

20 Q. I understand. *I understand that you want to keep saying that. And,*
21 *again, I'm going to ask you: Is that a canned answer you've*
22 *prepared?*

23 A. No.

- 23 • Ex. A (2024/11/07 Trial Tr.) at 517:19-518:17.

24 Q. It had not yet launched; right?

25 A. I mean, as I mentioned previously, launching --

26 Q. *I understand. I understand that you say "launching" could mean*
27 *a lot of things, and it could cover a huge time period. Okay.*

28 A. Yes.

Q. *We get that.* It hadn't been presented to be commercially available
yet?

A. They did not mention that in the JPMorgan conference, no.

1 Q. Okay. So back to what I was saying. You were already attacking
 2 Guardant's Reveal before it was even put into the stream of commerce;
 3 right?

4 A. No. I don't know when -- Q1 could be January 1. Q1 could be
 5 February. You know, I don't know when exactly they launched.

6 Q. Okay. That wasn't something you reviewed?

7 A. No.

8 *Q. Because "launch" could be so vague. It could be a year and a half.
 9 You can move it up or back, however you want; right? Exhibit 94, the
 10 email thread about these slides showed Guardant had a 91 percent
 11 sensitivity for recurrence detection with surveillance samples; right?*

12 A. Sorry. Where are you looking?

- 13 • Ex. A (2024/11/07 Trial Tr.) at 524:22-525:7.

14 Q. And he's talking about those very slides, Guardant slides from
 15 JPMorgan, confirmed launching MRD in Q1. *Apparently, they actually
 16 don't take the position that a launch could be up to 18 months.* So I
 17 want you to look at the part, second sentence that says -- well, the first
 18 [as read]: "They are misrepresenting their data. They do not have 91
 19 percent sensitivity at the landmark time point, but that's what the slide
 20 makes it look like." Do you see that?

21 A. Yes, I do.

- 22 • Ex. A (2024/11/07 Trial Tr.) at 525:16-19.

23 Q. That's not what I'm asking, sir. *Let me see if -- and I want to ask
 24 you another question. Is it part of your strategy as a witness to use up
 25 as much time as possible knowing that we're all on the clock?*

- 26 • Ex. A (2024/11/07 Trial Tr.) at 561:13-20.

27 Q. And you were already getting ready for a rebuttal. You wanted a
 28 key opinion leader; right?

A. To provide their perspective, correct.

Q. Again, before you had even seen the study; right?

A. *We saw the study at ESMO 2020 before --*

Q. *You saw a poster.* You had not read the study because it hadn't even
 been published yet by Dr. Parikh; right?

A. It had not formally been published in a journal.

29 These tactics are inappropriate and prejudicial, and Natera requests that the Court preclude
 30 Guardant's counsel from continuing to employ them.

31 DATED: November 11, 2024

32 QUINN EMANUEL URQUHART &
 33 SULLIVAN, LLP

34 By /s/ Kevin P.B. Johnson
 35

1 Kevin P.B. Johnson
2 Attorneys for NATERA, INC., a Delaware
3 corporation, Defendant and Counterclaim Plaintiff
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

ATTESTATION

I, Andrew J. Bramhall, am the ECF user whose ID and password are being used to file the above document. In compliance with Local Rule 5-1(i)(3), I hereby attest that Kevin P.B. Johnson has concurred in the filing of the above document.

By /s/ Andrew J. Bramhall

Andrew J. Bramhall